Angiography Contrast Media

Angiography Contrast Media Market Outlook

The global angiography contrast media market is expected to reach approximately USD 5.6 billion by 2035, growing at a CAGR of around 5.2% during the forecast period from 2025 to 2035. The growth of this market can be attributed to the increasing prevalence of cardiovascular diseases and the rising number of diagnostic imaging procedures that require precise imaging techniques. Additionally, technological advancements in imaging modalities, coupled with a growing geriatric population that is more susceptible to vascular diseases, further fuel the demand for angiography contrast media. The healthcare industry's increasing focus on improving diagnostic accuracy and patient outcomes also plays a crucial role in driving the market’s growth. Furthermore, the rising awareness regarding the benefits of early disease detection and treatment options is expected to continue supporting market expansion.

Growth Factor of the Market

Several growth factors are propelling the angiography contrast media market forward. The increasing prevalence of chronic diseases, particularly cardiovascular and neurological disorders, necessitates advanced imaging techniques, thus boosting the demand for contrast media. Furthermore, technological advances in imaging modalities, such as the enhancement of X-ray, MRI, and CT scans, allow for clearer and more accurate imaging, leading to better diagnostic outcomes. Public awareness campaigns highlighting the importance of early diagnosis also contribute to the increased demand for diagnostic imaging services. Additionally, with a growing focus on minimally invasive procedures and outpatient care, there is a shift towards the usage of contrast media that can enhance procedural efficacy. The advent of novel contrast agents that minimize adverse reactions and improve patient safety is also a significant factor influencing market growth.

Key Highlights of the Market

• The market is projected to witness a substantial CAGR of 5.2% during the forecast period from 2025 to 2035.
• North America is expected to dominate the market, accounting for nearly 40% of the total market share.
• The rise in the prevalence of cardiovascular diseases is driving the demand for angiographic procedures.
• Technological advancements and innovations in contrast media formulations are expected to enhance market growth.
• Growing awareness about the benefits of early disease detection is propelling the adoption of diagnostic imaging.

By Product Type

Iodinated Contrast Media:

Iodinated contrast media is one of the most widely used types for various imaging procedures, especially in X-ray and CT angiography. The iodine-based contrast agents are preferred due to their high radiopacity and ability to enhance the visibility of blood vessels and organs during imaging tests. Their extensive application across numerous diagnostics is fueled by their effectiveness in providing clear images that are crucial for accurate diagnoses. Moreover, the continuous development of new formulations, including non-ionic and low-osmolar iodinated contrast media, is helping to reduce adverse reactions, further enhancing their market penetration. The growth in the use of these agents is projected to remain strong, especially as medical imaging technology continues to evolve.

Gadolinium-based Contrast Media:

Gadolinium-based contrast media are predominantly utilized in MR angiography due to their paramagnetic properties, which enhance the quality of MRI images. These agents are particularly advantageous for patients with allergies to iodine, providing a safe alternative for contrast-enhanced imaging. The increasing prevalence of conditions requiring MR imaging, such as neurological disorders and cardiovascular diseases, is anticipated to drive the demand for gadolinium-based agents. Furthermore, ongoing research into improving the safety profile of these agents and their application in new imaging techniques will likely support their market growth in the coming years.

Barium-based Contrast Media:

Barium-based contrast media are primarily used in gastrointestinal studies, enhancing the visibility of the gastrointestinal tract during X-ray examinations. Although their primary application is outside of traditional vascular imaging, barium contrast media play a significant role in comprehensive diagnostic assessments, supporting the diagnosis of conditions that may indirectly affect vascular health. The steady demand for barium-based media in diagnostic imaging procedures is expected to sustain its market presence. Innovations in formulation to reduce gastrointestinal side effects and improve patient experience are also likely to bolster the growth of this segment within the angiography contrast media market.

Microbubble Contrast Media:

Microbubble contrast media are a relatively newer entrant specialized in ultrasound imaging. Their ability to enhance the echogenicity of blood flow makes them ideal for cardiovascular applications, particularly in assessing myocardial perfusion and vascular abnormalities. The growing interest in non-invasive imaging techniques has propelled microbubble agents into the spotlight, as they offer minimal side effects and quick clearance from the body. Ongoing studies exploring their use in various other applications, including oncology and liver imaging, are expected to expand their market presence, making them a key area of growth in the angiography contrast media market.

Others:

This category includes various other contrast agents that do not fall into the mainstream classifications, such as new experimental agents and combination contrast media. The continuous advancement in imaging technologies has led to the development of innovative agents designed to enhance imaging quality while minimizing adverse effects. Research and development activities focusing on the efficacy and safety of these new agents create opportunities for their entry into the market. As healthcare providers increasingly seek advanced imaging solutions, the segment of other contrast media is poised for growth, driven by evolving clinical needs and technological advancements.

By Application

X-ray Angiography:

X-ray angiography remains one of the most conventional and commonly utilized applications for angiography contrast media, especially for vascular imaging. The effectiveness of iodinated contrast agents in providing clear images of blood vessels has cemented their place in this field. With the increasing incidence of cardiovascular diseases, the demand for X-ray angiography is rising steadily. Technological advancements, such as digital angiography, contribute to improved image quality and reduced radiation exposure, further driving the application of angiography contrast media in this segment. Consequently, X-ray angiography will continue to be a significant end-use application, reflecting market stability and potential for growth in the years ahead.

MR Angiography:

Magnetic Resonance Angiography (MRA) is a non-invasive imaging technique that utilizes gadolinium-based contrast media to visualize blood vessels and assess blood flow. The increasing adoption of MRI technology in diagnosing vascular diseases, coupled with the growing awareness of the benefits of non-invasive imaging methods, is driving the demand for MR angiography. The safety profile of gadolinium-based agents, especially for patients with iodine allergies, makes them a preferred choice in many cases. As advancements in MRI technology occur, including high-resolution imaging and faster scan times, the application of MR angiography is expected to continue expanding, significantly impacting the overall angiography contrast media market.

CT Angiography:

CT angiography has gained significant traction owing to its ability to provide high-resolution images of blood vessels in a short period. The use of iodinated contrast media is crucial for enhancing the visualization of vascular structures during these examinations. The increasing prevalence of heart diseases and the need for rapid diagnostics have spurred the growth of CT angiography. Moreover, advancements in CT technology, such as multi-slice and dual-energy CT, are enhancing the efficacy of these procedures, leading to a higher demand for angiography contrast media. Consequently, this application is projected to witness substantial growth, further solidifying its importance within the overall market.

Others:

The “Others” category encompasses various applications, including peripheral angiography and pediatric angiography, where specific imaging techniques and protocols are utilized. While these applications may not dominate the market like X-ray, MR, or CT angiography, they are still significant contributors to the overall demand for angiography contrast media. The increasing recognition of the importance of diagnosing vascular conditions in diverse populations drives growth in these niche applications, and as new procedures and technologies emerge, this segment is likely to evolve, creating further opportunities for contrast media manufacturers.

By Distribution Channel

Hospitals:

Hospitals represent the largest distribution channel for angiography contrast media, accounting for a considerable share of the market. Various imaging departments within hospitals, including radiology, cardiology, and surgical units, rely heavily on contrast media for diagnostic and interventional procedures. The increasing patient volume and the prevalence of cardiovascular diseases necessitate the continued use of contrast media in hospital settings. Furthermore, hospitals are often equipped with cutting-edge imaging technology, allowing for a higher throughput of procedures and subsequently increasing the demand for angiography contrast media. As healthcare services evolve, hospitals are expected to maintain their dominant position in the distribution of these essential imaging agents.

Diagnostic Imaging Centers:

Diagnostic imaging centers are emerging as key players in the distribution of angiography contrast media, capturing a significant portion of the market share. These centers are increasingly equipped with advanced imaging technology, attracting patients seeking specialized diagnostic services. The convenience and accessibility offered by diagnostic imaging centers contribute to their growing popularity, particularly for outpatient procedures. Moreover, as healthcare shifts toward outpatient care, the demand for angiography contrast media in these centers is expected to rise, driven by the growing need for timely and accurate diagnostic imaging services. This trend reflects a shift in patient preferences and a growing reliance on specialized diagnostic facilities.

Ambulatory Surgical Centers:

Ambulatory surgical centers (ASCs) are becoming increasingly important as a distribution channel for angiography contrast media, primarily due to the rise in outpatient surgical procedures. ASCs offer a cost-effective alternative for patients undergoing minor vascular interventions, which often require the use of contrast media. The convenience of quick procedures and the shorter recovery times associated with ASCs make them an attractive option for patients and healthcare providers alike. The growth of outpatient surgical procedures is anticipated to positively impact the demand for angiography contrast media in ASCs, leading to increased market opportunities in this segment.

Others:

The “Others” category includes various alternative channels such as online suppliers, pharmacies, and research institutions. While these channels currently represent a smaller share of the market, they are expected to grow in significance over time. Online platforms are becoming increasingly popular for the procurement of medical supplies, including contrast media, due to convenience and competitive pricing. As the healthcare landscape continues to evolve and adapt to technological advancements, the role of these alternative distribution channels is likely to expand, creating opportunities for manufacturers and suppliers in the angiography contrast media market.

By Ingredient Type

Iodine:

Iodine-based contrast media are the most commonly used agents in angiographic procedures due to their strong radiopaque properties. They are predominantly utilized in X-ray and CT angiography, where they provide high-contrast images of blood vessels and tissues. The demand for iodine-based contrast is primarily driven by the increasing number of diagnostic imaging procedures and the rising prevalence of chronic diseases that necessitate such imaging tests. The continuous development of new formulations with improved safety profiles and reduced side effects is expected to sustain the growth of this ingredient type in the angiography contrast media market.

Gadolinium:

Gadolinium is primarily used in MR angiography and represents a significant component of the angiography contrast media market. Gadolinium-based agents are essential for enhancing the quality of MRI images by improving the visualization of blood flow and vascular structures. The growing recognition of the safety and efficacy of gadolinium-based contrast agents, especially for patients with iodine allergies, is driving their adoption. With advancements in MRI technology and increasing applications in various clinical scenarios, the demand for gadolinium-based contrast media is expected to rise, contributing to overall market growth.

Barium:

Barium is mainly used in gastrointestinal imaging but holds relevance in angiography studies for evaluating related vascular conditions. While its primary market share in the angiography contrast media sector is limited, it still plays a role in comprehensive diagnostic assessments. The ongoing demand for barium-based contrast in X-ray examinations is expected to sustain its presence in the market. As development continues in improving the formulations and addressing side effects, the barium segment has the potential to maintain its relevance in the angiography contrast media market.

Microbubbles:

Microbubbles are gaining traction in the angiography contrast media market, primarily for ultrasound applications. Their unique properties enhance the echogenicity of blood flow, making them valuable for cardiovascular assessments. The increasing focus on non-invasive imaging techniques is propelling the adoption of microbubble contrast agents. Moreover, ongoing research exploring their use in various applications, including oncology and liver imaging, is expected to expand their market presence. As new indications and formulations emerge, the growth of the microbubble segment is likely to significantly impact the angiography contrast media market.

Others:

This category includes various alternative ingredients used in the formulation of angiography contrast media. With the continuous advancement in imaging technologies, innovative agents are being developed to enhance image quality while minimizing risks of adverse reactions. Research and development activities focused on improving the safety and efficacy of these alternative agents are expected to drive growth in this segment. As healthcare providers increasingly seek advanced imaging solutions, the emergence of new ingredients presents opportunities for manufacturers to diversify their product offerings and meet evolving clinical needs.

By Region

In North America, the angiography contrast media market is expected to dominate due to the region's advanced healthcare infrastructure and high prevalence of cardiovascular diseases. The market share is projected to account for nearly 40% of the global total, supported by significant investments in medical imaging technology and a growing number of diagnostic imaging centers. The increasing adoption of advanced imaging techniques, coupled with a strong emphasis on early disease diagnosis, is anticipated to catalyze the growth of the angiography contrast media market in North America. Furthermore, the presence of key market players and ongoing research and development activities further solidify North America's position as a leading region in this sector, with a projected CAGR of 5.5% through 2035.

Europe is also poised for significant growth in the angiography contrast media market, owing to the increasing prevalence of chronic diseases and advancing imaging technologies. The region is expected to hold approximately 30% of the global market share, driven by rising healthcare expenditure and the implementation of innovative imaging modalities. The growing demand for minimally invasive diagnostic procedures is further contributing to market expansion. Additionally, initiatives aimed at enhancing patient outcomes through early diagnosis and treatment are expected to support the demand for angiography contrast media in Europe. The market is projected to grow at a CAGR of around 4.8% from 2025 to 2035.

Opportunities

The angiography contrast media market presents numerous opportunities for growth and expansion, particularly in developing regions where healthcare infrastructure is rapidly improving. The increasing demand for advanced imaging technologies in emerging markets, such as Asia Pacific and Latin America, creates significant potential for manufacturers to introduce innovative and affordable contrast media solutions. Additionally, as diagnostic imaging becomes more integrated within primary healthcare settings, the need for contrast media for various applications is expected to rise. Collaborations between healthcare providers and contrast media manufacturers can facilitate the adoption of new agents and technologies, ultimately enhancing patient care and diagnostic accuracy. Moreover, the growing focus on personalized medicine and targeted therapies presents an opportunity to develop specialized contrast agents that can provide enhanced imaging for specific indications and patient populations.

Another key opportunity lies in the continuous research and development of novel contrast agents designed to reduce adverse reactions and improve safety profiles. As healthcare providers increasingly emphasize patient safety and the minimization of risks associated with contrast media, innovation in this area can lead to increased market share for companies that successfully launch safer alternatives. Furthermore, educational initiatives aimed at healthcare professionals to improve awareness about the benefits and proper use of angiography contrast media can drive demand. By capitalizing on these opportunities, companies can foster growth and enhance their position in the rapidly evolving angiography contrast media market.

Threats

Despite the growth potential, the angiography contrast media market faces several threats that could impact its trajectory. One of the primary concerns is the rising incidence of adverse reactions associated with certain contrast agents, particularly iodinated and gadolinium-based media. Reports of allergic reactions, nephrotoxicity, and gadolinium deposition disease have raised safety concerns among healthcare providers and patients alike. Such apprehensions may lead to decreased usage of these agents and a subsequent decline in market demand. Additionally, the regulatory landscape surrounding the approval and use of contrast media is becoming increasingly stringent, which could slow down the introduction of new products and innovations in the market.

Another significant threat is the growing popularity of alternative imaging modalities, such as molecular imaging and hybrid imaging techniques, which may reduce the reliance on traditional angiography procedures. These innovations could lead to a shift in preference among healthcare providers and patients, potentially impacting the demand for angiography contrast media. Furthermore, the emergence of competitor products, including non-invasive imaging solutions that do not require contrast agents, could pose challenges to traditional contrast media usage. To mitigate these threats, market players must focus on improving the safety and efficacy of their products while investing in educational initiatives to raise awareness of the benefits of angiography contrast media.

Competitor Outlook

• GE Healthcare
• Bayer AG
• Bracco Imaging
• Guerbet
• Siemens Healthineers
• Fujifilm Holdings Corporation
• Philips Healthcare
• Canon Medical Systems Corporation
• Roche Diagnostics
• Hologic, Inc.
• Merck KGaA
• Covidien (Medtronic)
• Janssen Pharmaceuticals
• Mallinckrodt Pharmaceuticals
• Lantheus Medical Imaging

The competitive landscape of the angiography contrast media market is characterized by the presence of several prominent players, each vying for market share through innovation, partnerships, and strategic expansions. Major companies such as GE Healthcare and Bayer AG lead the market with their extensive product portfolios and established distribution networks. Both companies have invested heavily in research and development, often collaborating with healthcare institutions to improve existing contrast agents and develop new formulations that cater to a wider range of diagnostic imaging needs. Their strategic focus on enhancing patient safety and minimizing adverse reactions positions them favorably within the competitive landscape.

Bracco Imaging and Guerbet are other significant players in the angiography contrast media market, recognized for their specialized contrast agents and commitment to innovation. Bracco's range of iodinated contrast media and its focus on enhancing imaging quality through technological advancements have contributed to its strong market presence. Similarly, Guerbet's dedication to developing gadolinium-based agents for MR angiography underscores its role as a key player in the sector. Both companies are likely to maintain their competitive edge by continuing to invest in R&D and expanding their product lines. Furthermore, as the industry shifts towards safety-centric solutions, their efforts to address patient concerns regarding adverse reactions will enhance their brand reputation and customer loyalty.

Siemens Healthineers and Philips Healthcare are also noteworthy competitors in the angiography contrast media market, operating at the intersection of imaging technology and pharmaceutical solutions. Their comprehensive imaging systems, coupled with proprietary contrast media, provide integrated and efficient solutions for healthcare providers. This synergy allows them to benefit from market trends that favor advanced imaging modalities and enhanced diagnostic capabilities. Furthermore, both companies have been actively engaging in strategic mergers and acquisitions to enhance their product offerings and capture new market segments. Their ability to adapt to changing market dynamics and leverage technological advancements will be crucial for maintaining their competitive positions.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Guerbet
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Bayer AG
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Merck KGaA
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 GE Healthcare
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Hologic, Inc.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Bracco Imaging
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Roche Diagnostics
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Philips Healthcare
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Covidien (Medtronic)
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Siemens Healthineers
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Janssen Pharmaceuticals
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Lantheus Medical Imaging
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Mallinckrodt Pharmaceuticals
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Fujifilm Holdings Corporation
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Canon Medical Systems Corporation
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Angiography Contrast Media Market, By Application
    • 6.1.1 X-ray Angiography
    • 6.1.2 MR Angiography
    • 6.1.3 CT Angiography
    • 6.1.4 Others
  • 6.2 Angiography Contrast Media Market, By Product Type
    • 6.2.1 Iodinated Contrast Media
    • 6.2.2 Gadolinium-based Contrast Media
    • 6.2.3 Barium-based Contrast Media
    • 6.2.4 Microbubble Contrast Media
    • 6.2.5 Others
  • 6.3 Angiography Contrast Media Market, By Ingredient Type
    • 6.3.1 Iodine
    • 6.3.2 Gadolinium
    • 6.3.3 Barium
    • 6.3.4 Microbubbles
    • 6.3.5 Others
  • 6.4 Angiography Contrast Media Market, By Distribution Channel
    • 6.4.1 Hospitals
    • 6.4.2 Diagnostic Imaging Centers
    • 6.4.3 Ambulatory Surgical Centers
    • 6.4.4 Others

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Angiography Contrast Media Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Angiography Contrast Media market is categorized based on

By Product Type

• Iodinated Contrast Media
• Gadolinium-based Contrast Media
• Barium-based Contrast Media
• Microbubble Contrast Media
• Others

By Application

• X-ray Angiography
• MR Angiography
• CT Angiography
• Others

By Distribution Channel

• Hospitals
• Diagnostic Imaging Centers
• Ambulatory Surgical Centers
• Others

By Ingredient Type

• Iodine
• Gadolinium
• Barium
• Microbubbles
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• GE Healthcare
• Bayer AG
• Bracco Imaging
• Guerbet
• Siemens Healthineers
• Fujifilm Holdings Corporation
• Philips Healthcare
• Canon Medical Systems Corporation
• Roche Diagnostics
• Hologic, Inc.
• Merck KGaA
• Covidien (Medtronic)
• Janssen Pharmaceuticals
• Mallinckrodt Pharmaceuticals
• Lantheus Medical Imaging